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represented	 the	 test	 positively,	 emphasizing	 its	 ability	 to	 “personalize”	 treatment	
pathways,	though	many	also	pointed	to	inherent	uncertainties	with	regards	the	pos-
sibility	of	cancer	recurrence.
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anticipated	 that	 the	 identification	 of	 specific	 genetic	 alterations	
within	tumours	will	lead	to	treatment	regimes	tailored	to	individual	
patients.2	 As	 an	 example	 of	 this	 novel	 approach,	 gene	 expression	
profiling	 may	 now	 be	 offered	 as	 part	 of	 routine	 National	 Health	




the	 predicted	 benefit	 of	 chemotherapy	 for	 preventing	 recurrence	
may	be	unclear	when	assessed	on	protein	 receptor	 status	and	 tu-
mour	grade	alone.	Available	 as	part	of	NHS	care	 as	of	April	 2015	
(initially	in	England),	the	Oncotype	DX	test	uses	gene	expression	pro-
filing	to	predict	the	risk	of	cancer	recurrence	in	these	patients	and	
identify	 those	 who	 are	 most	 likely	 to	 benefit	 from	 adjuvant	
chemotherapy.
Oncotype	DX	assesses	the	activity	of	21	genes	in	breast	can-
cer	 tissue.	 The	 corresponding	 results	 are	 prognostic,	 indicating	
the	 likelihood	 of	 a	 woman’s	 cancer	 returning	 within	 10	years	
when	 treated	 with	 hormone	 therapy	 alone.	 The	 cancer	 is	 as-
signed	a	continuous	“recurrence	score”	(from	0	to	100),	and	a	risk	
category	for	recurrence:	 low	(<18),	 intermediate	 (18-	30)	or	high	
(≥31).3	 The	 recurrence	 score	 is	 a	 predictor	 of	 benefit	 from	 the	
addition	of	 chemotherapy	 to	 hormone	 therapy	 for	 disease-	free	
survival.4	In	clinical	practice,	both	the	score	and	risk	categoriza-
tion	 are	used	by	 clinicians	 and	patients	 to	 assist	 chemotherapy	
decisions.	For	those	positioned	at	low	risk	of	recurrence,	studies	
have	 suggested	 that	 these	 patients	 are	 unlikely	 to	 derive	 great	
benefit	 from	adjuvant	 treatment.5	 Patients	 in	 this	 category	 are	
not	 recommended	 to	 proceed	with	 chemotherapy,6	which	 is	 it-
self	associated	with	(sometimes	severe)	side-	effects	and	suffer-
ing.7	 Chemotherapy	 is	 recommended	 for	 those	 patients	 with	 a	
high	 recurrence	 score,	 as	 it	 has	 been	 shown	 to	 bestow	 signifi-
cant	advantage	for	disease-	free	survival	compared	with	hormone	




diate	 score,	 treatment	 recommendations	 often	 involve	 further	
discussions	 with	 the	 patient,	 alongside	 consideration	 of	 wider	
clinical	parameters	and	patient	preferences.6,9
In	2013,	guidance	published	by	the	National	Institute	for	Health	
and	 Care	 Excellence	 (NICE)	 acknowledged	 the	 uncertainties	 sur-
rounding	 treatment	 decision	making	 for	 patients	 with	 early-	stage	






or	 tests	 that	 help	 people	 decide	whether	 or	 not	 to	



















making	 by	 patients	 is	 complex	 and	 situated.	 Treatment	 decisions	




that	 patients	 vary	 in	 the	 degree	 to	 which	 they	 wish	 to	 take	 full	
ownership	over	 treatment	decisions	 in	health	care.14,15	Alongside	
contemporary	 shifts	 in	 the	provision	of	 care,	 individuals	 are	 also	
seeking	advice	and	support	for	medical	decision	making	beyond	the	
clinic	through	virtual	platforms.16	The	Internet	can	be	a	source	of	
second	opinions,	 advice	 regarding	 symptoms	or	 side-	effects,	 and	






patients	 are	 today	 presented	 with	 large	 amounts	 of	 information	
about	 their	 condition	 and	 a	 range	 of	 different	 options,	 including	




To	 improve	 understanding	 of	 how	 novel	 techniques	 might	 be	
shaping	patient	decision	making,	 in	what	follows	we	explore	wom-



































the	 social	 sciences	 that	 Internet	use	 is	enmeshed	with	contempo-
rary	experiences	of	health	and	illness.16,20	Indeed,	as	landscapes	of	










April	 2015,	 when	 the	 test	 was	 approved	 for	 NHS	 use,	 until	 May	
2017.	Discussion	threads	identified	by	the	search	were	copied	into	






one	 of	 the	 seven	 online	 forums	 featuring	 the	 word	 “Oncotype”	
contained	 68	 threads	within	 the	 date	 range.	Discussion	 threads	
on	 this	 forum	 contained	 between	 4	 and	 75	 individual	 posts.	 To	





were	 excluded	 from	 the	 recent	 diagnosis	 forum,	 for	 example	
if	 the	 technique	was	merely	 named	when	 recounting	 treatment	





additional	 ongoing	 thread	 containing	 over	 5000	 posts;	 this	 also	
centred	around	support	in	the	context	of	recent	diagnosis.	In	the	





not	 undergone	 the	 test	 themselves,	 but	 who	 had	 outlined	 anec-
dotal	or	media	 reported	 information	about	 the	Oncotype	DX	 test,	
and	from	those	who	had	unsuccessfully	attempted	to	access	gene	





















refined	 key	 themes.	 These	were	 then	 shared	 between	 all	 authors	
and	discussed	and	developed	drawing	on	verbatim	data,	to	cultivate	
overarching	focal	points	for	the	presentation	of	findings.




safeguarding	 the	 interests	of	 those	 involved	 in	or	 affected	by	 the	
research	remaining	paramount.24	However,	the	use	of	online	mate-
rial	 demands	 new	 ethical	 considerations,	 with	 issues	 of	 informed	
consent,	anonymity	and	confidentiality	not	adequately	addressed	by	
guidelines	applied	to	more	established	research	methods.	In	line	with	
the	 deliberative	 process	 advocated	by	 the	Association	of	 Internet	
Researchers,25	we	consulted	existing	online	research	studies	when	
deciding	upon	our	strategy.	Due	 to	 the	personal	nature	of	 the	ac-
counts	presented	within	online	 forums,	we	contacted	 forum	mod-










In	 what	 follows,	 we	 show	 how	 the	 Oncotype	 DX	 test	 was	 rep-






possibility	of	cancer	 recurrence.	 In	doing	so,	we	highlight	 tensions	
between	 the	 claims	 of	 genomic	 testing	 to	 aid	 treatment	 decision	
making,	 and	 the	 uncertainties	 and	 anxieties	 which	 the	 procedure	
could	provoke	or	leave	unresolved.
3.1 | Representations of gene expression testing 
within online environments
Many	 discussions	 of	 Oncotype	 DX	 represented	 the	 test	 as	 facili-
tating	 treatment	 decision	 making,	 echoing	 the	 rationale	 outlined	
within	the	2013	NICE	guidance	cited	above.	For	example,	one	user	
of	 a	 cancer	 support	 charity	 forum	explained	 that	 gene	expression	
profiling	 “help[s]	 make	 informed	 decisions	 about	 chemo[therapy]”	
(DiamondMary, Jan 2017),	and	another	declared	she	was	“glad	I	took	
the	 test	 because	 it	 did	 help	my	 decision	 in	 the	 end”	 (SandyP, Jan 
2017).
Related	 to	 this,	 several	 users	 emphasized	 the	 test’s	 ability	 to	
provide	“personalized”	information	about	cancer.	For	example,	one	
woman	advised	others	 to	undergo	 the	 test	because	 “it’s	based	on	
you	and	you	can	then	make	an	informed	decision”	(Stacey1954, Jan 
2016).	Another	described	that	“what	 it	does	 is	show	whether	your	




The	 onco[type	 DX]	 test	 is	 a	 very	 good	 test,	 which	
provides	 statistical	 evidence	 based	 upon	 your	 tu-















Scepticism	 of	 these	 more	 widely	 used	 tools	 was	 also	 visible	
amongst	others,	with	MayP (January 2017)	describing	 these	as	 “only	
a	general	indicator	based	on	past	recovery	data	that	can	be	quite	old.”	
In	the	same	thread,	Pumpkin	noted	that	where	“generalised	tools	could	

















3.2 | Gene expression testing and treatment 
decision making
Oncotype	DX’s	production	of	a	single	figure	to	indicate	recurrence	
risk,	 and	 corresponding	 recommendation	 to	 proceed	 (or	 not)	 to	
     |  5ROSS et al.
chemotherapy,	was	welcomed	by	many	women.	Some	attributed	a	
particular	power	to	the	test	score	in	shaping	their	treatment	choices.	


















I	 have	 [an]	 Oncotype	 DX	 score	 of	 17	 so	 no	 chemo	
	 MollyC,	Feb	2017
These	 crude	 presentations	 of	 treatment	 pathways	 were	 com-
mon	on	 the	 forum	posts	we	analysed.	Here,	we	see	 that	uncertain-
ties	 surrounding	 the	 prediction	 of	 recurrence	 risk,	 and	 complexities	
of	 treatment	 decision	making	 visible	within	 other	 forum	 responses,	
and	described	within	existing	sociological	 literature	[eg,	12,13],	were	
obscured.	These	users	depicted	 their	decision	not	 to	go	ahead	with	




















risk,	 the	 intermediate	 risk	 category	 is	 not	 associated	 with	 clear	
guidance	with	regards	adjuvant	chemotherapy.	Throughout	posts,	
this	was	described	as	the	“up	to	you	zone”	(SueDev April 2017)	or	













help	but	 it’s	a	 low	percentage.	 [The	oncologist]	 said	









ing	 to	 further	 treatment.	SueDev	 invokes	a	notion	of	 future	 “regret”	
as	shaping	her	treatment	decisions.	This	accords	with	language	used	
by	patients	within	 existing	 studies,	whereby	 cancer	 is	 positioned	 as	













The	 other	 factor	 influencing	 my	 decision	 was	 the	
knowledge	that	studies	have	been	conducted	where	
the	 intermediate	 group	 was	 redefined	 as	 11	 to	 26	









cision	making	 within	 some	 online	 posts,	 these	 examples	 show	 that	









sult	with	particular	 authority	 in	 shaping	 treatment	 choices,	others	
expressed	scepticism	of	the	test’s	ability	to	aid	treatment	decision	




tumour	 cells.	 Users’	 experiences,	 including	memories	 of	 historical	
treatment,	 reinforced	 this	 sense	 of	 the	 unpredictability	 of	 cancer.	
For	example:
Just	 2	years	 after	 finishing	 Chemo	 I	 was	 diagnosed	
with	bone	 [metastases]	 to	my	sternum!	So	a	sneaky	
























































ment	 reflections	 on	 this	 technology	 in	 online	 spaces.	 Comments	
from	 some	women	 positioned	Oncotype	 DX	 results	 as	 “personal-
ized,”	 interpreting	the	 information	 it	provides	as	 “tailored”	 to	their	
cancer,	 and	 as	 superior	 to	 existing	 techniques	 assisting	 chemo-
therapy	decision	making.	This	may	be	shaped	by	wider	discourses	
     |  7ROSS et al.











Nevertheless,	 despite	 its	purported	aim	 to	 facilitate	 treatment	
decision	 making	 by	 predicting	 recurrence	 and	 estimating	 chemo-











were	 situated	 within	 emotional	 responses	 to	 chemotherapy	 and	
cancer	in	the	present,	but	also	possible	futures	and	long-	term	con-
sequences	 of	 decision	 making.	 Through	 the	 accounts	 described	
above,	 we	 have	 also	 demonstrated	 that	 interpretations	 of	 results	
are	 informed	by	 sociocultural	 depictions	of	 cancer	 and	 treatment,	
with	chemotherapy	and	suffering	depicted	as	necessary	 to	recover	




Decision	 making	 was	 particularly	 complex	 where	 recurrence	
scores	signalled	an	intermediate	risk	of	cancer	recurrence.	In	these	
cases,	women	often	appealed	to	other	forum	users	for	guidance	on	




and	 its	 recurrence,	where	 the	disease	was	shown	 to	ultimately	be	
unpredictable,	and	treatment	efficacy	uncertain.	Many	women	were	
thus	aware	of	the	limitations	of	gene	expression	profiling,	which	re-





Overall,	 our	 analysis	 has	 shown	 that	 gene	 expression	 profiling	
did	 not	 always	 straightforwardly	 facilitate	 decision	 making	 with	












en’s	 negotiations	 of	 these	 novel	 techniques.	 Accessing	 and	 inter-
acting	within	online	spaces	 further	distributes	decision	making,	as	
treatment	 options	 themselves	 become	more	 diffuse.	 Patients	 are	
today	required	to	make	sense	of	new	forms	of	clinical	 information	
and	 medical	 techniques,	 with	 these	 experienced	 by	 smaller,	 sub-
groups	 of	 individuals.	 Women	 used	 online	 forums	 to	 document	
competing	 treatment	 options	 and	 emotions,	 to	 share	 experiences	
and	to	seek	advice	from	others.	Online	research	methods	therefore	
enabled	us	to	observe	aspects	of	decision	making	as	an	evolving	pro-
cess	distributed	amongst	a	wide	 range	of	 settings	and	 individuals,	
enrolling	unknown	and	anonymous	others	over	time	and	space.12,13
Whilst	 online	 forums	 have	 provided	 insight	 into	 intimate	 ac-
counts	of	treatment	decision	making	as	shaped	by	gene	expression	
profiling,	their	use	to	access	women’s	experiences	does	have	limita-
tions.	We	cannot	 say	with	certainty	 that	we	were	able	 to	capture	
accounts	from	a	diverse	group	of	women,	with	Internet	access	likely	
to	 reflect	wider	 social	 and	 structural	 inequalities.36	 This	 research,	
however,	did	not	intend	to	be	generalizable	in	a	statistical	sense,	but	





















regret	 for	declining	 treatment.	This	emphasizes	 the	 importance	of	
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